# NHLBI Training Program in Pharmacoepidemiology

> **NIH NIH T32** · JOHNS HOPKINS UNIVERSITY · 2021 · $354,642

## Abstract

PROJECT SUMMARY / ABSTRACT
Pharmacoepidemiology is a bridge science that uses tools from pharmacology, epidemiology and clinical
medicine to understand the use, safety and effectiveness of drugs in large populations. The need for experts in
this field has never been greater. During the past decade, dozens of new therapies have been brought to
market, including products made from living cells, or biologics, to address common and costly heart, lung and
blood conditions ranging from homozygous familial hypercholesterolemia to idiopathic pulmonary fibrosis to
Hemophilia A. With the rise in access to promising yet expensive drugs comes the need to study their benefits
and risks in diverse populations as well as to understand best use of these medicines to improve human
health. In addition, many of pharmacoepidemiology's tools and methods are also highly relevant to the study of
use, safety and effectiveness of other medical products including diagnostics, devices, and drug-device
combinations. We propose a training program in pharmacoepidemiology for pre- and post-doctoral trainees at
the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine. These
institutions are exceptionally well suited to this task. The Bloomberg School of Public Health is the oldest and
largest School of Public Health in the world, having celebrated its centennial this year, while the Johns Hopkins
School of Medicine is an internationally renowned leader in scientific research and clinical medicine. Our
proposed program will leverage a wealth of human capital and material resources at Johns Hopkins to provide
comprehensive, longitudinal, and integrated training and professional development opportunities to future
leaders in the field. We will use this award to train scientists who will identify and address fundamental
questions about the use, safety and effectiveness of medicines and other medical products for the treatment of
heart, lung and blood diseases. Given the strengths of our faculty and trainee pool, we will also support the
development of innovative methods to do so. Thus, our trainees will develop skills to generate evidence that
can be used to address the needs of patients, clinicians, payers, regulators and other stakeholders, and in so
doing, improve the optimal use of medicines to treat heart, lung and blood diseases in the United States.

## Key facts

- **NIH application ID:** 10088463
- **Project number:** 5T32HL139426-04
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** G. Caleb Alexander
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $354,642
- **Award type:** 5
- **Project period:** 2018-01-01 → 2022-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10088463

## Citation

> US National Institutes of Health, RePORTER application 10088463, NHLBI Training Program in Pharmacoepidemiology (5T32HL139426-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10088463. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*